Volume 5.10 | Mar 21

Prostate Cell News 5.10 March 21, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Reduced 64Cu Uptake and Tumor Growth Inhibition by Knockdown of Human Copper Transporter 1 in Xenograft Mouse Model of Prostate Cancer
RNA interference-mediated knockdown of human copper transporter 1 was associated with the reduced cellular uptake of 64Cu and the suppression of prostate cancer cell proliferation in vitro. [J Nucl Med] Abstract
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Restoration of PPP2CA Expression Reverses Epithelial-to-Mesenchymal Transition and Suppresses Prostate Tumor Growth and Metastasis in an Orthotopic Mouse Model
Effect on prostate cancer phenotype was studied in vitro and in orthotopic mouse model, and immunohistochemical/histological analyses performed to assess proliferation/apoptosis and confirm metastatic lesions. [Br J Cancer] Abstract

Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon Drug Induced DNA Damage under Hypoxia
Researchers showed that prostate cancer cells with mutant p53 were resistant to the poly(ADP-ribose) polymerase inhibitor, veliparib and the DNA-damaging topoisomerase I inhibitor Camptothecin-11 or SN38 under hypoxia. [Mol Pharmacol] Abstract | Full Article

MicroRNA-494-3p Targets CXCR4 to Suppress the Proliferation, Invasion, and Migration of Prostate Cancer
The biological effect of miR-494-3p on prostate cancer cells proliferation, apoptosis, migration, and invasion was measured by MTT, TUNEL, flow cytometry, migration, and invasion assays. [Prostate] Abstract

Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer
Scientists determined the efficacy somatostatin analogue octreotide combined with a low dose of docetaxel using castration resistant prostate cancer cells and to investigate the involved molecular mechanisms in vitro. [PLoS One] Full Article

NMR-Based Evaluation of the Metabolic Profile and Response to Dichloroacetate of Human Prostate Cancer Cells
Researchers evaluated the metabolic profile of human prostate cancer cells that have different metastatic potential and to determine their response to dichloroacetate using NMR technology. [NMR Biomed] Full Article

Comparative Effects of Soy Phytoestrogens and 17ß-Estradiol on DNA Methylation of a Panel of 24 Genes in Prostate Cancer Cell Lines
Scientists investigated the effects of soy phytoestrogens and the natural estrogen 17ß-estradiol to determine whether one of the estrogen receptors is mobilized for the action of these compounds on DNA methylation. [Nutr Cancer] Abstract

Sulforaphane and TRAIL Induce a Synergistic Elimination of Advanced Prostate Cancer Stem-Like Cells
The established androgen-independent prostate cancer cell lines DU145 and PC3, with enriched cancer stem cells (CSC) features, and primary patient-derived prostate CSCs were treated with sulforaphane and recombinant soluble TRAIL. Scientists largely found a stronger effect of sulforaphane on CSC properties compared to TRAIL, though the agents acted synergistically when applied in combination. [Int J Oncol]
Abstract | Download Full Article

Thrombomodulin Mediates the Migratory Ability of Hormone-Independent Prostate Cancer Cells through the Regulation of Epithelial-to-Mesenchymal Transition Biomarkers
Higher levels of thrombomodulin (TM) transcription and translation were found in DU-145 cells and were negatively correlated with the low migratory ability of DU-145 cells. After silencing TM expression in DU-145 cells, cell growth decreased, but cell adhesion and migration dramatically increased. [Tumor Biol] Abstract

CLINICAL RESEARCH

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
This Phase II trial randomized chemotherapy-naïve men with progressing castration-resistant prostate cancer to receive figitumumab every three weeks with docetaxel/prednisone or docetaxel/prednisone alone. [Clin Cancer Res] Abstract

Androgen Dynamics and Serum PSA in Patients Treated with Abiraterone Acetate
Researchers analyzed the potential of abiraterone acetate to reduce androgen levels below lower limits of quantification and explored the association with changes in PSA decline in metastatic castration-resistant prostate cancer patients. [Prostate Cancer Prostatic Dis] Full Article

Clinical Pharmacology of an Atrasentan and Docetaxel Regimen in Men with Hormone-Refractory Prostate Cancer
Investigators evaluated potential pharmacokinetic interactions between docetaxel and atrasentan as part of a Phase I/II clinical trial. [Cancer Chemother Pharmacol] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
TGF-ß Cascade Regulation by PPP1 and Its Interactors – Impact on Prostate Cancer Development and Therapy
The authors discuss the role of phosphoprotein phosphatase 1 (PPP1) in the regulation of several transforming growth factor beta (TGF-ß) signaling members and how the subversion of this pathway is related to prostate cancer development. Furthermore, current challenges on the protein phosphatases field as new targets to cancer therapy are addressed. [J Cell Mol Med] Full Article

Biomarkers in Prostate Cancer: What’s New?
The authors provide an overview of the current state of biomarkers for prostate cancer, with a focus on biomarkers approved by the US Food and Drug Administration as well as biomarkers available from Clinical Laboratory Improvement Amendment-certified clinical laboratories within the last 1-2 years. [Curr Opin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
Advaxis, Inc. announced that it has signed an agreement with the University of California, San Francisco under which Lawrence Fong, M.D. will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. [Advaxis, Inc.] Press Release

New Prostate Cancer Treatments to be Fast-Tracked
Clinical trials of new drugs to treat the most aggressive form of prostate cancer are expected to be underway in Brisbane within three years, thanks to Movember Revolutionary Team Award grant that is fast-tracking global research into the disease. [Queensland University of Technology] Press Release

Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naïve Advanced Prostate Cancer
Astellas Pharma Inc. and Medivation Inc. announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval of XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy. [Astellas Pharma Inc.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW American Society of Clinical Oncology (ASCO) 50th Annual Meeting
May 30 – June 3, 2014
Chicago, Illinois

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellows – Small-Molecule Drugs in the Treatment of Prostate Cancer Bone Metastasis (Georgia Regents University Cancer Center)

Studentship – Targeting WW Domain Function in Ubiquitin Ligases Overexpressed in Prostate Cancer (University of East Anglia)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer (Mayo Clinic- Rochester)

Postdoctoral Fellow – Biomarker Discovery In Prostate Cancer (University of California, San Francisco)

Postdoctoral Position – Cancer Biology/Genomics (Weill Cornell Medical College)

Experienced Researcher – Detection of Prostate Cancer Biomarkers (Dublin City University)

Postdoctoral Fellow – Role of Mitochondria in Cancer Progression (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us